Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy

Isaac Yang, Nancy G. Huh, Zachary A. Smith, Seunggu (Jude) Han, Andrew T. Parsa

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Recent advancements have made radiation and chemotherapy the standard of care for newly diagnosed glioblastomas. The use of these therapies has resulted in an increased diagnosis of pseudoprogression and radiation-induced necrosis. Standard MRI techniques are inadequate in differentiating tumor recurrence from posttreatment effects. Diagnosis of a posttreatment lesion as glioma recurrence rather than radiochemotherapy or immunotherapy treatment effect is critical. This increase in accuracy plays a role as newer immunotherapies incurring posttreatment effects on MRI emerge. Advancements with magnetic resonance spectroscopy, diffusion-weighted imaging, and functional positron emission tomography scans have shown promising capabilities. Further investigations are necessary to assess the imaging algorithms and accuracy of these modalities to differentiate true glioma recurrence from radiotherapy or immunotherapy treatment effect.

Original languageEnglish (US)
Pages (from-to)181-186
Number of pages6
JournalNeurosurgery clinics of North America
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Chemoradiotherapy
Glioma
Immunotherapy
Recurrence
Radiation
Glioblastoma
Standard of Care
Positron-Emission Tomography
Necrosis
Magnetic Resonance Spectroscopy
Radiotherapy
Therapeutics
Drug Therapy
Neoplasms

Keywords

  • Bevacizumab
  • Glioma
  • Immunotherapy
  • Pseudoprogression
  • Radiation-induced necrosis
  • Temozolomide
  • Tumor recurrence

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy. / Yang, Isaac; Huh, Nancy G.; Smith, Zachary A.; Han, Seunggu (Jude); Parsa, Andrew T.

In: Neurosurgery clinics of North America, Vol. 21, No. 1, 01.01.2010, p. 181-186.

Research output: Contribution to journalReview article

Yang, Isaac ; Huh, Nancy G. ; Smith, Zachary A. ; Han, Seunggu (Jude) ; Parsa, Andrew T. / Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy. In: Neurosurgery clinics of North America. 2010 ; Vol. 21, No. 1. pp. 181-186.
@article{fcdc409b56e84380a11fefc0cfcdf658,
title = "Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy",
abstract = "Recent advancements have made radiation and chemotherapy the standard of care for newly diagnosed glioblastomas. The use of these therapies has resulted in an increased diagnosis of pseudoprogression and radiation-induced necrosis. Standard MRI techniques are inadequate in differentiating tumor recurrence from posttreatment effects. Diagnosis of a posttreatment lesion as glioma recurrence rather than radiochemotherapy or immunotherapy treatment effect is critical. This increase in accuracy plays a role as newer immunotherapies incurring posttreatment effects on MRI emerge. Advancements with magnetic resonance spectroscopy, diffusion-weighted imaging, and functional positron emission tomography scans have shown promising capabilities. Further investigations are necessary to assess the imaging algorithms and accuracy of these modalities to differentiate true glioma recurrence from radiotherapy or immunotherapy treatment effect.",
keywords = "Bevacizumab, Glioma, Immunotherapy, Pseudoprogression, Radiation-induced necrosis, Temozolomide, Tumor recurrence",
author = "Isaac Yang and Huh, {Nancy G.} and Smith, {Zachary A.} and Han, {Seunggu (Jude)} and Parsa, {Andrew T.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.nec.2009.08.003",
language = "English (US)",
volume = "21",
pages = "181--186",
journal = "Neurosurgery Clinics of North America",
issn = "1042-3680",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy

AU - Yang, Isaac

AU - Huh, Nancy G.

AU - Smith, Zachary A.

AU - Han, Seunggu (Jude)

AU - Parsa, Andrew T.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recent advancements have made radiation and chemotherapy the standard of care for newly diagnosed glioblastomas. The use of these therapies has resulted in an increased diagnosis of pseudoprogression and radiation-induced necrosis. Standard MRI techniques are inadequate in differentiating tumor recurrence from posttreatment effects. Diagnosis of a posttreatment lesion as glioma recurrence rather than radiochemotherapy or immunotherapy treatment effect is critical. This increase in accuracy plays a role as newer immunotherapies incurring posttreatment effects on MRI emerge. Advancements with magnetic resonance spectroscopy, diffusion-weighted imaging, and functional positron emission tomography scans have shown promising capabilities. Further investigations are necessary to assess the imaging algorithms and accuracy of these modalities to differentiate true glioma recurrence from radiotherapy or immunotherapy treatment effect.

AB - Recent advancements have made radiation and chemotherapy the standard of care for newly diagnosed glioblastomas. The use of these therapies has resulted in an increased diagnosis of pseudoprogression and radiation-induced necrosis. Standard MRI techniques are inadequate in differentiating tumor recurrence from posttreatment effects. Diagnosis of a posttreatment lesion as glioma recurrence rather than radiochemotherapy or immunotherapy treatment effect is critical. This increase in accuracy plays a role as newer immunotherapies incurring posttreatment effects on MRI emerge. Advancements with magnetic resonance spectroscopy, diffusion-weighted imaging, and functional positron emission tomography scans have shown promising capabilities. Further investigations are necessary to assess the imaging algorithms and accuracy of these modalities to differentiate true glioma recurrence from radiotherapy or immunotherapy treatment effect.

KW - Bevacizumab

KW - Glioma

KW - Immunotherapy

KW - Pseudoprogression

KW - Radiation-induced necrosis

KW - Temozolomide

KW - Tumor recurrence

UR - http://www.scopus.com/inward/record.url?scp=70450205337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450205337&partnerID=8YFLogxK

U2 - 10.1016/j.nec.2009.08.003

DO - 10.1016/j.nec.2009.08.003

M3 - Review article

C2 - 19944976

AN - SCOPUS:70450205337

VL - 21

SP - 181

EP - 186

JO - Neurosurgery Clinics of North America

JF - Neurosurgery Clinics of North America

SN - 1042-3680

IS - 1

ER -